Copyright
©The Author(s) 2020.
World J Gastrointest Pathophysiol. Apr 12, 2020; 11(2): 32-42
Published online Apr 12, 2020. doi: 10.4291/wjgp.v11.i2.32
Published online Apr 12, 2020. doi: 10.4291/wjgp.v11.i2.32
Figure 4 Comparison of rates of Clinical remission and Endoscopic remission over multiple timepoints in those who switched to and remained on alternative aminosalicylate vs those who switched back and remained on balsalazide.
A: Clinical remission; B: Endoscopic remission.
- Citation: van Langenberg DR, Cheng RKY, Garg M. Outcomes of a drug shortage requiring switching in patients with ulcerative colitis. World J Gastrointest Pathophysiol 2020; 11(2): 32-42
- URL: https://www.wjgnet.com/2150-5330/full/v11/i2/32.htm
- DOI: https://dx.doi.org/10.4291/wjgp.v11.i2.32